Bioexcelife
Performance evaluation is one of the most important requirements for IVD manufacturers under the EU IVDR.
Under the In Vitro Diagnostic Medical Devices Regulation, manufacturers must show that their IVD test is not only technically functional, but also scientifically valid and clinically meaningful.
In simple words, performance evaluation answers one key question:
Can your IVD test do what it claims to do, accurately and reliably, in the intended clinical setting?
This is why performance evaluation is not just a regulatory document. It is the evidence foundation of your IVD device.
Why Performance Evaluation Matters Under IVDR
The IVDR has raised the level of evidence expected from IVD manufacturers.
Earlier, many IVDs entered the market with limited Notified Body involvement. Under IVDR, the expectations are much stricter. Manufacturers must now provide stronger evidence to support the intended purpose, risk class, clinical use, and performance claims of the device.
This means that a Performance Evaluation Report, or PER, cannot be prepared as a simple summary. It must clearly explain how the available evidence supports the safety, performance, and clinical value of the IVD.
A weak performance evaluation can lead to Notified Body questions, certification delays, and compliance gaps.
The Three Pillars of Performance Evaluation
A strong IVDR performance evaluation is built on three main pillars: scientific validity, analytical performance, and clinical performance.
Scientific validity explains the relationship between the analyte and the clinical condition. For example, it shows why a biomarker is relevant for detecting, diagnosing, monitoring, or predicting a disease.
Analytical performance shows how well the test measures the analyte. This may include accuracy, precision, sensitivity, specificity, repeatability, reproducibility, and detection limits.
Clinical performance shows how well the test result relates to the clinical condition or intended use in the target population.
Together, these three pillars help prove that the IVD test is reliable, relevant, and useful in clinical practice.
PER Is More Than a Report
Many manufacturers think performance evaluation ends once the PER is written.
That is not correct.
Under IVDR, performance evaluation is a continuous process. The PER must remain updated throughout the lifecycle of the device. It should reflect new evidence, post-market findings, complaints, trends, and Post-Market Performance Follow-up data.
This makes the PER a living document.
If new information shows a change in performance, emerging risks, or gaps in clinical evidence, the manufacturer must review and update the performance evaluation.
PMS and PMPF Connection
Performance evaluation must connect with Post-Market Surveillance and Post-Market Performance Follow-up.
PMS helps collect real-world information after the IVD is placed on the market. PMPF helps confirm whether the device continues to perform as intended in real clinical use.
This connection is critical.
If PMS or PMPF data shows performance concerns, the PER should reflect those findings. If no concerns are found, the data can support continued compliance and strengthen the evidence base.
In short, PMS and PMPF help keep the performance evaluation current and defensible.
Common Mistakes in IVDR Performance Evaluation
One common mistake is having a broad intended purpose but limited performance evidence.
For example, if the intended purpose covers a wide population or multiple clinical settings, the evidence must support that full scope. If the evidence only covers a narrow use case, Notified Bodies may raise questions.
Another mistake is weak linkage between claims and evidence. Every performance claim should be supported by scientific validity, analytical performance, or clinical performance data.
Some manufacturers also prepare generic PMPF plans that do not address real performance uncertainties. Under IVDR, PMPF activities should be meaningful and linked to the device’s actual risks and evidence gaps.
What Notified Bodies Expect
Notified Bodies expect a clear and logical performance story.
They want to see that the intended purpose is well defined, the evidence is relevant, and the conclusions are supported.
They also expect traceability between the intended purpose, claims, performance studies, risk management, PMS, PMPF, and the final PER conclusion.
If these elements do not connect, the submission becomes weak.
A strong PER should not just describe evidence. It should explain why the evidence is enough.
Why IVD Manufacturers Should Start Early
Performance evaluation should not be left until the final stage of submission.
If evidence gaps are found late, manufacturers may need additional studies, literature reviews, PMPF activities, or documentation updates. This can delay certification and market access.
Starting early helps manufacturers identify missing evidence, refine claims, plan PMPF properly, and build a stronger technical file.
For IVD manufacturers, early planning is one of the best ways to reduce regulatory risk under IVDR.
Performance evaluation under IVDR is not just about proving that a test works.
It is about proving that the test is scientifically valid, analytically reliable, and clinically meaningful.
A strong Performance Evaluation Report helps build confidence for regulators, Notified Bodies, healthcare professionals, and patients.
Under IVDR, the strongest PERs are not the longest. They are the ones that are clear, evidence-based, traceable, and lifecycle-focused.
How Bioexcel Can Help
At Bioexcel, we support IVD manufacturers with performance evaluation planning, PER preparation, scientific validity reports, analytical and clinical performance evidence review, PMPF strategy, and IVDR technical documentation alignment.
We help ensure your performance evaluation is not just complete, but clear, compliant, and review-ready.
Need support with Performance Evaluation under IVDR? Partner with Bioexcel for a stronger and smoother path to compliance.
